RMD — Resmed Share Price

As of Today at 19:18 UTC, shares in Resmed are trading at $185.86. This share price information is delayed by 15 minutes.

Shares in Resmed last closed at $185.86 and the price had moved by -17.96% over the past 365 days. In terms of relative price strength the Resmed share price has underperformed the S&P500 Index by -33.75% over the past year.

The overall consensus recommendation for Resmed is Buy. You can view the full broker recommendation list by unlocking its StockReport.

The Resmed dividend yield is 0.99% based on the trailing twelve month period.

Last year, Resmed paid a total dividend of $1.84, and it currently has a trailing dividend yield of 0.99%. We do not have any data on when Resmed is to next pay dividends.

We do not have data on when Resmed is to next pay dividends.  The historic dividend yield on Resmed shares is currently 0.99%.

To buy shares in Resmed you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

As of the previous close price of $185.86, shares in Resmed had a market capitalisation of $27.34bn.

Here are the trading details for Resmed: 

• Country of listing: United States
• Exchange: NYQ
• Ticker Symbol: RMD

Based on an overall assessment of its quality, value and momentum Resmed is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

The analyst consensus target price for shares in Resmed is $202.68.  That is 9.05% above the last closing price of $185.86.

Analysts covering Resmed currently have a consensus Earnings Per Share (EPS) forecast of $7.41 for the next financial year.

An important predictor of whether a stock price will go up is its track record of momentum.  Price trends tend to persist, so it's worth looking at them when it comes to a share like Resmed. Over the past six months, its share price has outperformed the S&P500 Index by +13.13%.

As of the last closing price of $185.86, shares in Resmed were trading +6.87% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

The Resmed PE ratio based on its reported earnings over the past 12 months is 23.17. The shares last closed at $185.86. 

The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.

The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.

Resmed's management team is headed by: 

• Peter Farrell - NEC
• Robert Douglas - PRE
• Michael Farrell - CEO
• Brett Sandercock - CFO
• Bobby Ghoshal - CEX
• Jim Hollingshead - CEX
• Justin Leong - CEX
• Urvashi Tyagi - CTO
• David Pendarvis - CAD
• Ronald Taylor - LED
• Carol Burt - IND
• Jan De Witte - IND
• Karen Drexler - IND
• Harjit Gill - IND
• Richard Sulpizio - IND